"In a traditional corneal transplant, the central part of the cornea is removed and a donor cornea is sutured in its place. Image courtesy of Dr. Edward Holland, University of Cincinnati.
Ten years after a transplant, a cornea fro"...
Mechanism Of Action
Akten™ (lidocaine hydrochloride ophthalmic gel) is a local anesthetic agent that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and persists for 5 to 30 minutes.
Lidocaine may be absorbed following topical administration to mucous membranes. Its rate and extent of absorption depend upon various factors such as concentration, the specific site of application, viscosity of the agent, and duration of exposure.
The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.
Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative Ndealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacologic/toxicologic actions of these metabolites are similar to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline.
Studies of lidocaine metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2 hours. Because of the rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics. The half-life may be prolonged twofold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites.
A total of 209 subjects were enrolled, with 54, 51, 53, and 51 subjects randomized to the sham, Akten™ (lidocaine hydrochloride ophthalmic gel) 1.5%, Akten™ (lidocaine hydrochloride ophthalmic gel) 2.5%, and Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% groups, respectively. Ocular anesthesia was achieved within 5 minutes of anesthetic application by 47 of 51 subjects (92%) in the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group.
The mean time to anesthesia onset ranged from 20 seconds to 5 minutes was not affected by Akten™ (lidocaine hydrochloride ophthalmic gel) dose. The mean time to anesthesia onset was approximately 60 seconds, with a median onset time of 40 seconds for the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group. Among the subjects in the Akten™ (lidocaine hydrochloride ophthalmic gel) groups who achieved anesthesia within 5 minutes, approximately 90% had achieved anesthesia within 60 seconds of application.
The duration of anesthesia generally ranged from approximately 5 minutes to 30 minutes, with mean anesthesia durations of approximately 15 minutes for the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group.
Approximately 84% of the subjects in the Akten™ (lidocaine hydrochloride ophthalmic gel) 3.5% group experienced anesthesia for at least 5 minutes, approximately 55% of subjects experienced anesthesia for 10 minutes or longer and 27% experienced anesthesia for 15 minutes or longer. The anesthetic effect of additional applications of Akten™ (lidocaine hydrochloride ophthalmic gel) has not been evaluated.
Last reviewed on RxList: 11/4/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Akten Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.